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Abstract
Background: Maternal kidney disease (acute kidney injury (AKI), advanced chronic kidney disease (CKD),
dependence on dialysis or a kidney transplant) has a substantial impact on pregnancy, with risks of significant
perinatal morbidity. These pregnancies require integrated multidisciplinary care to manage a complex and often
challenging clinical situation. The ability to deliver optimal care is currently hindered by a lack of understanding
around prevalence, management and outcomes in Australia. This study aims to expand an evidence base to
improve clinical care of women with serious kidney impairment in pregnancy.
Methods/design: The “Kidney Disease in Pregnancy Study” is a national prospective cohort study of women with
stage 3b-5 CKD (including dialysis and transplant) and severe AKI in pregnancy, using the Australasian Maternity
Outcomes Surveillance System (AMOSS). AMOSS incorporates Australian maternity units with > 50 births/year (n =
260), capturing approximately 96% of Australian births. We will identify women meeting the inclusion criteria who
give birth in Australia between 1st August 2017 and 31st July 2018. Case identification will occur via monthly
review of all births in Australian AMOSS sites and prospective notification to AMOSS via renal or obstetric clinics.
AMOSS data collectors will capture key clinical data via a web-based data collection tool. The data collected will
focus on the prevalence, medical and obstetric clinical care, and maternal and fetal outcomes of these high-risk
pregnancies.
Discussion: This study will increase awareness of the issue of serious renal impairment in pregnancy through
engagement of 260 maternity units and obstetric and renal healthcare providers across the country. The study
results will provide an evidence base for pre-pregnancy counselling and development of models of optimal clinical
care, clinical guideline and policy development in Australia. Understanding current practices, gaps in care and areas
for intervention will improve the care of women with serious renal impairment, women with high-risk pregnancies,
their babies and their families.
Keywords: Cohort study, Population, Pregnancy, Pregnancy outcome, Chronic kidney disease, Acute kidney injury,
Kidney transplantation, Renal dialysis
Background
Chronic Kidney Disease (CKD) is an under-recognised,
serious and increasing major health problem, which dis-
proportionately affects Indigenous peoples and lower so-
cioeconomic groups [1–3] . The prevalence of CKD
amongst Australian mothers is rising due to the
population rise in diabetes, obesity and older age in
pregnancy [4]. Over 5% of Australian women of child-
bearing age have albuminuria or abnormal estimated
GFR (eGFR) indicating CKD [2]. In Australia in 2016,
25% of all women with a functioning renal transplant
and 51% of all female incident end-stage kidney disease
(ESKD) cases were in women of reproductive age (15–
44 years) [5]. Parenthood is a major concern for women
with CKD, and women experience important fears and
uncertainties about risks to their own and their baby’s
health [6, 7]. Women of childbearing age with CKD may
face difficult decisions about parenthood while
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experiencing significant comorbidity and impairment to
activities of daily living. Navigating paths to parenthood
via complex shared decision-making can be challenging
and accurate outcome data would enable evidence-based
risk stratification [7].
There is a knowledge gap regarding the burden of
CKD in pregnancy in the Australian context. Determin-
ing the prevalence of kidney disease in pregnancy has
not been easy, due to varying definitions, changing sta-
ging systems and poor capture of renal markers (serum
creatinine and urine protein) in pregnancy cohorts [8,
9]. The Australia and New Zealand dialysis and trans-
plant registry (ANZDATA) reports pregnancy rates for
chronic dialysis and transplant recipients of 3.3/1000
person-years and 20/1000 person-years respectively but
is likely under-reported [10–12]. Rates of advanced stage
CKD (Stage 3b-4), and non-chronic Acute Kidney Injury
(AKI) occurring in pregnancy in Australia are unknown.
This information is important when developing mater-
nity and renal services.
There is currently no data on how significant kidney
disease in pregnancy (CKD stage 3b-5, dialysis, trans-
plant or AKI) impacts upon pregnancy care and how it
is managed in Australia. Registry and perinatal datasets
currently active in Australia collect some data items and
past analyses of the ANZDATA registry have provided
some information on pregnancy rates and basic preg-
nancy outcomes [10, 13]. However, these provide min-
imal insights into obstetric and perinatal adverse events,
therapy and interventions required during pregnancy,
models of care delivered, and utilisation of health care
resources including hospitalisation and other events.
This knowledge is important to obtain as pregnancy in
women with CKD is associated with worse obstetric and
perinatal outcomes including preterm birth, small for
gestational age, and pre-eclampsia and gestational hyper-
tension [14, 15]. The risk is increased, even in women
with Stage 1 CKD [16, 17] and continues to rise as CKD
stage advances [15, 18, 19]. Pre-conception eGFR< 40
ml/min, poorly controlled hypertension and proteinuria
are factors associated with higher rates of obstetric and
perinatal complications [20–23]. As pre-conception
renal function worsens, the risk of “stage shift” or deteri-
oration in renal function also increases, and may neces-
sitate dialysis during pregnancy [9, 24, 25].
Pregnancies in women receiving chronic dialysis are
rare due to the reduced fertility of women with advanced
kidney failure, and are particularly challenging in terms
of maternal care [8]. The recognition that intensive dia-
lysis improves outcomes has led to changes in clinical
practice and counselling for women with advanced CKD
[19, 24, 26, 27]. Australian women receiving chronic dia-
lysis have a 27% fetal loss rate compared with 7% among
all pregnancies [10]. Among live births, 75% are preterm
and more than 50% of such babies have birth weights
less than the 10th centile [10]. Outcomes are better for
women who commence dialysis after conception com-
pared with those who conceive while receiving chronic
dialysis [10, 28]. Even after successful kidney transplant-
ation, these pregnancies continue to have high rates of
pre-eclampsia (> 25%), prematurity and poor fetal
growth (> 50%) [12, 13, 29]. Worse graft function (serum
creatinine > 110 μmol/L) during pregnancy can predict
risk of pre-eclampsia and kidney function trajectory in-
cluding significantly higher rates of graft loss within 3
years of giving birth [29].
The incidence of Acute Kidney Injury (AKI) in preg-
nancy has decreased in recent years in developed coun-
tries, mainly due to improvement in peripartum sepsis
care [30]. However, AKI still represents a potentially
catastrophic event in pregnancy, caused predominantly
by pre-eclampsia [31]. There is also enhanced awareness
and understanding of newer conditions such as atypical
haemolytic uraemic syndrome [32]. AKI in one preg-
nancy is associated with worse outcomes in the next
[33]. Approximately 1/10,000 pregnancies are compli-
cated by AKI that requires dialysis, which was associated
with poor perinatal outcomes and increased maternal
death rate in one Canadian study [34]. There are no
Australian data regarding frequency, causes and out-
comes of pregnancy-related AKI, and this remains an
important area to investigate.
Severe CKD and AKI in pregnancy, while uncommon,
cause a high burden of maternal and perinatal morbidity
[14, 15, 34]. A lack of information regarding outcomes
for women with these conditions in Australia including
the maternal mortality and morbidity, model of care,
perinatal outcomes, and access to services, presently
limits the health service providers’ ability to counsel and
manage affected women. The model of care required for
such high risk pregnancies may not be equitably avail-
able to all women at higher risk, particularly those who
are Indigenous, geographically isolated, from a lower so-
cioeconomic status (SES) or from a culturally and lin-
guistically diverse (CALD) group.
The aim of this study is to determine the Australian
prevalence, pregnancy-related and pre-existing maternal
and renal morbidity and perinatal outcomes associated
with serious maternal kidney disease in pregnancy; and
to describe patterns of presentation, pregnancy manage-
ment and models of care and adequacy of healthcare de-
livery in these pregnancies. We will achieve this by
development of a new framework for capture of mater-
nal and fetal outcomes for cases of significant kidney
disease in pregnancy, using the existing Australasian
Maternity Outcomes Surveillance System (AMOSS) re-
search platform which is embedded in many maternity
units across Australia. We hypothesise that mothers with
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CKD and AKI will have a substantial pregnancy related
and pre-existing medical morbidity, and that babies born
to these mothers will have higher prematurity and con-
sequent perinatal morbidity. Adverse outcomes may be
related to modifiable factors in pre-pregnancy and ante-
natal care, including access to specialised services, im-
proved blood pressure management and dialysis
treatment, fetal surveillance and timing of delivery. The
study findings will inform a guideline and policy devel-




Using the existing AMOSS maternity surveillance sys-
tem embedded in 260 maternity hospitals in Australia
we will identify cases of significant CKD (Stage 3b-5 in-
cluding dialysis and transplant) and severe AKI in
pregnancy.
1. To determine the prevalence, and geographical
distribution.
2. Utilise survey data to determine pregnancy
outcomes (maternal and perinatal), renal outcomes,
models of care, and maternity management
Study design
A national, prospective cohort study using the Australa-
sian Maternity Outcomes Surveillance System (AMOSS)
. The AMOSS methods have been described in detail
elsewhere [35, 36]. In brief, AMOSS is an established
surveillance and research system across maternity units
in Australia and New Zealand to study rare but clinically
important and severe conditions in pregnancy, which
place a disproportionate burden on women, their fam-
ilies and healthcare systems. AMOSS has access to al-
most all (95% [260/275]) eligible Australian maternity
units with more than 50 births/year, capturing an esti-
mated 96% of women giving birth in a hospital in
Australia.
Study population, case definition and inclusion criteria
The study population will include all women giving birth
in participating Australian AMOSS sites between 1st
August 2017 and 31st July 2018. Cases of serious kidney
disease giving birth in participating Australian AMOSS
sites during the study period will be collected. Table 1
shows the inclusion criteria. Birth is defined as the birth
of one or more live or stillborn infants of at least 20
weeks gestation or at least 400 g birthweight. Women
not giving birth (e.g. pregnancy ending in miscarriage or
termination of pregnancy < 20 weeks gestation) or with
early-stage CKD and less severe AKI will be excluded
from the study.
Assessment of renal function in pregnancy – selection of
inclusion criteria
Serum creatinine is a widely used marker of renal func-
tion in non-pregnant patients, which varies depending
on muscle mass, age, and ethnicity. Renal function in
non-pregnant patients is evaluated by calculating the es-
timated glomerular filtration rate (eGRF), with formulae
derived from populations using gender, age, ethnicity
and serum creatinine measurement. The eGFR is most
commonly calculated using the CKD-EPI formula and is
routinely provided when reporting serum creatinine in
the adult population by laboratories in Australia [37].
However, eGFR formulae are not valid for use during
pregnancy, where serum creatinine usually falls due to
renal physiological changes, and where a serum creatin-
ine > 80-90 mmol/L usually reflects a degree of renal im-
pairment. Therefore, in this study, eGFR will only be
used for pre-pregnancy serum creatinine values. As
shown in Table 2, in women aged 18–45 years, a pre-
pregnancy serum creatinine of 130–150 micromol/L or
Table 1 Inclusion criteria
All women in Australia who gave birth:
a. Between 1 August 2017 and 31 July 2018; AND
b. At least 20 weeks’ gestation and/or at least 400 g birth weight; AND
c. Who present with at least one of the following criteria:
1. A working kidney transplant (all women regardless of kidney
transplant function)
2. Receiving any long-term dialysis before conception and continuing
any dialysis during pregnancy.
3. Starting any dialysis during pregnancy (any dialysis - either once off,
temporary or permanent dialysis)
4. Known pre-conception eGFR < 45 ml/min/1.73m2 (known to have a
serum creatinine > 130–150 μmol/L before conception, regardless of the
serum creatinine reading during pregnancy)
5. Newly identified renal function impairment with any serum creatinine
reading of > 150 μmol/L on 2 readings at least 24 h apart during
pregnancy
Table 2 Pre-pregnancy serum creatinine and eGFR









aeGFR(ml/min/1.73m2) calculated for adult females at various ages within the
childbearing age range, using the CKD-EPI formula [45] without
ethnicity coefficients
beGFR < 45ml/min/1.73m2 indicates Stage 3b CKD. Therefore, all women with
pre-pregnancy serum creatinine ≥150micromol/L will have CKD Stage 3b
or higher
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more will reflect eGFR < 45ml/min/1.73m2 (CKD Stage
3b or higher) [38]. The data collector will obtain pre-
pregnancy serum creatinine measurements wherever
available, for all cases.
AMOSS data collectors based in each AMOSS partici-
pating site will complete two web-based data collection
forms for all women who fulfil the inclusion criteria for
the study (Fig. 1). The first survey form is the general
AMOSS data collection form utilised in all AMOSS stud-
ies, obtaining demographic characteristics such as mater-
nal age, hospital sector, comorbidity, smoking, and BMI,
and captured data on medical and obstetric history, ob-
stetric interventions and information about type of care,
and location of care. In addition this general survey col-
lects information regarding baby outcomes including birth
status, gestation, gender, birthweight, admission to inten-
sive or specialised care units, congenital abnormalities,
and neonatal morbidity and mortality (Additional file 1).
The second survey has been developed for this study
will capture specific renal information (Additional file 2):
1. General renal history: presentation; the underlying
cause of kidney disease; primary diagnosis including
kidney biopsy; biochemical data; proteinuria; blood
pressure; details of kidney disease management;
timing and model of antenatal care; and access to
specialist obstetric, obstetric medicine and
nephrology services.
2. Transplant history: transplant source; transplant
biopsy; anti-rejection treatment and therapeutic
monitoring.
3. Dialysis: commencement of dialysis during
pregnancy; dialysis modality; vascular access and
complications.
4. Medication and other therapies: medication used
prior to pregnancy; details of antihypertensive and
immunosuppressant medications.
5. Antenatal, birth and postpartum care: blood
pressure measurements; antenatal screening and
fetal growth scans; antenatal events, including
diagnoses of pre-eclampsia, placental abruption;
blood transfusion; and birth and post-partum
management.
Study outcomes
Primary outcomes: Prevalence rates of maternal AKI
and CKD in the general AMOSS birth (live or stillbirths)
cohort as per inclusion criteria. The rate will be
expressed as per 1000 maternities based on birth rates
for AMOSS hospitals during the study period.
Secondary outcomes will include: 1) Maternal obstetric
outcomes and complications – a range of outcomes dur-
ing antenatal, delivery and post-partum stages; 2) Mater-
nal renal outcomes including renal function, graft
function and commencement of dialysis; 3) Adequacy
and complications of dialysis therapy; 4) Transplant-
related complications including graft dysfunction and in-
fection; 5) Perinatal outcomes including birth outcomes
and adverse outcomes especially related to preterm birth
(Additional file 3).
Data collection
Electronic survey data will be collected via an encrypted
web-based data management system (the ‘AMOSS sys-
tem’). Record data will be kept on a secure server with
daily backup to an offsite facility. Where a data collector
is not able to complete a survey using the web-based
survey system, they may handwrite survey responses
Fig. 1 AMOSS surveillance and data collection workflow. *Hospital case identification. Clinical management/Hospital based obstetric and other
information systems. Morbidity and/or clinical review meetings. Direct and indirect notification
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using the PDF versions of surveys, and scan/send to
AMOSS where the survey will be entered on their behalf
by the AMOSS team.
AMOSS provides continuous education and support
for data collectors before the start of data collection.
This is achieved by disseminating the renal study proto-
col using the AMOSS newsletter, emails, phone calls
and presentations at hospitals and conferences. The
AMOSS team and investigators will provide support for
all data collectors regarding enquiries during the study
via emails, phone calls or site visits as requested.
Participant identification
We will identify study participants through multiple
sources: AMOSS surveillance; notification from nephrol-
ogists, obstetric physicians and obstetricians; audit com-
mittees; and review of routine data collection within
hospitals.
Sample size
Based on current international literature, which esti-
mates CKD Stage 3b-5 rate of 2 to 12 per 10,000; severe
AKI requiring dialysis as 1 per 10,000 pregnancies; esti-
mated 295,530 births ≥20 weeks gestation/year in par-
ticipating Australian AMOSS sites [34, 39–41]; and
allowing for potential early pregnancy losses; we esti-
mate identifying between 89 and 384 cases in 1 year.
Statistical analysis
We anticipate our analysis will largely utilise descriptive
statistics (frequency (percentage) for categorical data and
mean (standard deviation) or median (interquartile
range) for continuous data) will be used to summarise
the demographic characteristics, kidney disease data,
maternal and baby outcomes of women with advanced
CKD, dialysis, transplant and AKI. Cases will be
reviewed in depth to map patient care models. Maternal
and baby outcomes will be compared with Australian
norms. If sample size allows, odds ratios will be esti-
mated via logistic regression for outcomes and adjusted
for relevant parameters including demographic data
(maternal age, ethnicity); renal function, proteinuria and
blood pressure at conception; time from commencement
of dialysis or transplant; and dialysis modality and hours
(Additional file 4). Variables associated with outcomes in
the univariable analysis (p < 0.2) and other factors identi-
fied in the literature as potentially predictive will be en-
tered into multivariable logistic regression models. Final
models will be determined by taking into account the
final sample size for each study group, likely causal path-
way, collinearity, and clinical significance. Analysis of
variance (ANOVA) and generalised linear models will be
used to examine the change in maternal kidney function
during pregnancy. We will examine the distribution and
pattern of missing data for key study and outcome fac-
tors with high proportion of missing data. Multiple im-
putation will be performed for variables qualified as
‘missing at random’ [42]. For variables with pattern of
missing data unlikely to be ‘missing at random’, a ‘proxy’
category for missing data will be created for variables
with > 2% missing and a sensitivity analysis will be con-
ducted to explore the effect of missing data. A p-value <
0.05 or a confidence interval not including unity will be
considered statistically significant. All statistical analyses
will be performed using SPSS 24.0 software (Armonk,
NY, USA: IBM Corp.).
Discussion
This AMOSS study will highlight the issue of serious
kidney disease in pregnancy in Australia, with height-
ened awareness in approximately 260 maternity units
and among obstetric and renal healthcare providers
across the country. The study will focus on cases of ser-
ious kidney disease in pregnancy that, while uncommon,
can cause significant morbidity for mothers and babies,
present clinical complexity for clinicians, and place a
disproportionate burden on health care resources. The
study will fill an important knowledge gap on the preva-
lence and models of care for this high-risk cohort of
women.
The strengths of this study come from the AMOSS re-
search model, which encompasses 96% of hospital births
in Australia, and where cases can be identified prospect-
ively and data collected after birth. In addition, multiple
sources to identify eligible participants will increase the
ability to capture cases, thereby minimising missed
cases. The main challenge in this study will be the data
collection for women who (1) receive their obstetric and
renal care at different locations, or (2) receive renal care
at a non-AMOSS site. To overcome these challenges,
ethics approval was granted at most sites for the
AMOSS Project Coordinator to receive minimal identi-
fying details of prospective patients receiving renal care
at one site and pass those details on to the onsite
AMOSS data collector at the woman’s maternity hos-
pital. For women receiving renal care at a non-AMOSS
site, separate ethical and/or governance approval for
data collection at the specialist clinic and matching with
maternity data will be sought on a case-by-case basis.
The results of this study will be immediately relevant
and enable translation into clinical practice. Specifically,
we will.
a) Improve the evidence base for pre-pregnancy coun-
selling and pregnancy management, and will pro-
mote this as an important pathway towards
improved outcomes. We will identify healthcare
professional groups to target for strategic education
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in specialist and primary care, and mechanisms to
target high-risk women antenatally. Previous
AMOSS studies have led to important improve-
ments in safety and quality of care for pregnant
women suffering from rare and under-studied con-
ditions, where there is often a lack of data and clin-
ical experience to guide management.
b) Promote clinical guideline and policy development
in Australia by providing an evidence base
describing current models of care, and highlighting
gaps in care or risk factors for adverse outcomes.
Currently, there are no Australian guidelines or
policies to facilitate delivery of specialised
pregnancy care to women with renal disease.
c) Disseminate our findings to key stakeholders
(clinical providers - medical, midwifery, nursing,
allied health, government policy planners and
patient/consumer groups) involved in the care of
women with CKD and AKI, women with high-risk
pregnancy, their babies and their families. We will
develop resources for health providers and patients
through engagement with renal and pregnancy con-
sumer organisations.
d) Use this study to form the foundation for
developing new systems for ongoing data capture
regarding maternal kidney disease, including the
potential to re-purpose the data collection instru-
ment into an ongoing registry.
Given that no other studies have explored serious mater-
nal kidney disease in the Australian birth cohort, we antici-
pate the results will be of great interest to the obstetric and
renal community nationally and internationally.
Additional files
Additional file 1: General Information: Case report form is used to
collect general maternal and neonatal data. (PDF 411 kb)
Additional file 2: Renal Disease in Pregnancy: Case report form is used to
collect data specifically related to renal disease in pregnancy. (PDF 511 kb)
Additional file 3: Main outcome measurements: A list of the main
outcome measures that will form the basis of data analysis. (DOCX 12 kb)
Additional file 4: Selected covariates: The list of variables that we
expect to be associated with the outcomes. (DOCX 13 kb)
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